Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT01429376
First received: September 2, 2011
Last updated: September 6, 2011
Last verified: September 2011
  Purpose

The aim of the present study is:

  1. To investigate pulmonary function abnormalities (restriction, obstruction, diffusion impairment, mixed pulmonary defects) in patients with chronic heart failure (CHF) and to determine which of these pulmonary abnormalities prevail and to what extent.
  2. To determine the prevalence, underdiagnosis, and overdiagnosis of chronic obstructive pulmonary disease (COPD) as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
  3. To investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.

Condition Intervention
Heart Failure
Pulmonary Disease, Chronic Obstructive
Inflammation
Other: Pulmonary function tests
Other: Blood tests
Other: Questionnaires
Other: Chest radiograph

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: 1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?

Resource links provided by NLM:


Further study details as provided by Rijnstate Hospital:

Primary Outcome Measures:
  • Pulmonary function abnormalities [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Restriction, obstruction, diffusion impairment, mixed pulmonary defects

  • COPD prevalence, underdiagnosis, and overdiagnosis [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Patients with newly diagnosed COPD repeated spirometry after 3 months of standard treatment for COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.

  • Systemic inflammation [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Leukocytes, platelets, high sensitivity CRP.


Secondary Outcome Measures:
  • Quality of life [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Minnesota Living with Heart Failure Questionnaire (MLHFQ), on the day of initial pulmonary function tests and 3 months later.

  • Dyspnoea [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    modified Medical Research Council (MRC) dyspnea scale and 10-point Borg dyspnoea score, on the day of initial pulmonary function tests and 3 months later.

  • Independent predictors of COPD [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Patients characterisitcs, such as age, gender, body mass index, symptoms, smoking history, family history, and so on.


Enrollment: 234
Study Start Date: October 2009
Study Completion Date: June 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Pulmonary function tests
    Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
    Other: Blood tests

    First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).

    Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.

    Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR.

    Other: Questionnaires

    Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.

    All questionnaires were completed on the day of initial pulmonary function tests and three months later.

    Other: Chest radiograph
    Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
Detailed Description:
  1. The impact of chronic heart failure (CHF) on pulmonary function is incompletely understood and remains controversial. It is difficult to separate the contribution of stable CHF from underlying pulmonary disease and other confounding influences, such as changes due to normal ageing, obesity, environmental exposure (mainly smoking), stability of disease, a history of coronary artery bypass grafting, and other conditions that can lead to pulmonary function abnormalities. Studies have shown that isolated or combined pulmonary function impairment, such as diffusion impairment, restriction, and to a much lesser extent airway obstruction are common in patients with CHF and can contribute to the perception of dyspnoea and exercise intolerance. Pulmonary dysfunction increases with the severity of heart failure and provides important prognostic information. Most investigators compared pulmonary function in CHF patients with normal predicted values or control subjects. However, there is only a small body of literature addressing the prevalence of different pulmonary function abnormalities in patients with CHF. In addition, these studies have included (potential) heart transplant recipients, who represent one extreme of the heart failure spectrum. The aim of the present study was to investigate the prevalence of pulmonary function abnormalities in patients with CHF and to determine which of these pulmonary abnormalities prevail and to what extent.
  2. Chronic obstructive pulmonary disease (COPD) frequently coexists with CHF, leading to impaired prognosis as well as diagnostic and therapeutic challenges. However, lung functional data on COPD prevalence in CHF are scarce and COPD remains widely undiagnosed or misdiagnosed. The reported prevalence rates of COPD range from 9 to 41% in European cohorts and from 11 to 52% in North American patients with heart failure. The purpose of this study was to determine the prevalence, underdiagnosis, and overdiagnosis of COPD as determined by spirometry and according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria in patients with CHF.
  3. There is abundant evidence of increased systemic inflammation in both CHF and COPD and it is remarkable to observe the similarities of inflammation in both conditions. These inflammatory responses may provide a mechanistic bridge between COPD and cardiac co-morbidity. However, there is no information regarding systemic inflammation when CHF and COPD coexist. It is unknown whether the combination of these two diseases leads to increased systemic inflammation in comparison to CHF alone. The aim of this study was to investigate the presence of systemic inflammation, as measured by inflammatory parameters (leukocytes, platelets, high sensitivity CRP), in CHF patients with or without COPD.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic heart failure patients with left ventricular systolic dysfunction (left ventricular ejection fraction < 40%)
  • Outpatients
  • New York Heart Association (NYHA) class I-IV
  • 18 years and older
  • Informed consent

Exclusion Criteria:

  • Patients who do not meet the inclusion criteria
  • Patients who are not able to cooperate or undergo pulmonary function tests
  • Other diseases that can lead to obstructive lung function: asthma, cystic fibrosis
  • Malignancy with bad prognosis (survival < 6 months)
  • Hospitalisation to the pulmonary department in the past 6 weeks, in this case patients will have the pulmonary function tests ≥ 6 weeks after discharge
  • Patients who are already participating in another study within the cardiology department

Additional exclusion criteria for the first primary objective:

  • Disorders/diseases that can lead to pulmonary function impairment:

    • Pulmonary: lung surgery (lobectomy/pneumectomy), parenchymal neoplasms, interstitial lung disease, sarcoidosis, pneumoconioses, lung abscess, lobar pneumonia, post- infectious scarring, atelectasis, radiation fibrosis
    • Pleural: diffuse pleural thickening, mesothelioma, pleural effusion not due to heart failure, pneumothorax
    • Neuromuscular diseases: ALS, poliomyelitis, myopathy, bilateral diaphragmatic paralysis, high spinal cord lesions, myasthenia gravis
    • Abdominal: obesity (BMI > 35) (exclusion only from the restriction prevalence analysis)
    • Pericardial: major pericardial effusion
    • Large mediastinal processes
    • Collagen vascular diseases

Additional exclusion criteria for the third primary objective:

  • Active/recent infection
  • Febrile or inflammatory disease such as rheumatoid arthritis
  • Use of antibiotics or anti-inflammatory medication, such as etanercept, infliximab, systemic use of corticosteroids and NSAID's other than acetylsalicylic acid
  • Malignancy
  • Auto-immune disease
  • Collagenvascular disease
  • Gastro-intestinal disease (such as inflammatory bowel disease)
  • Recent operation (past 3 months)
  • Renal or liver failure
  • Thyroid disease
  • Obstructive sleep apnoea syndrome (OSAS)
  • Disorders that lead to thrombocytopenia/leukocytopenia or thrombocytosis/leukocytosis (hs-CRP analysis will take place in case these disorders do not affect hs-CRP)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01429376

Locations
Netherlands
Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6800 TA
Rijnstate Hospital
Zevenaar, Gelderland, Netherlands, 6903 ZN
Sponsors and Collaborators
Rijnstate Hospital
GlaxoSmithKline
Investigators
Principal Investigator: Armine G Minasian, MD Rijnstate Hospital, Arnhem, The Netherlands
  More Information

No publications provided

Responsible Party: Rijnstate Hospital
ClinicalTrials.gov Identifier: NCT01429376     History of Changes
Other Study ID Numbers: LTC-607-070409
Study First Received: September 2, 2011
Last Updated: September 6, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Rijnstate Hospital:
Chronic heart failure
Pulmonary function abnormalities/impairment
Restriction
Airway obstruction
Diffusion impairment
Pulmonary function tests
Chronic obstructive pulmonary disease (COPD)
Prevalence
Overdiagnosis
Underdiagnosis
Systemic inflammation
Diagnostic Errors

Additional relevant MeSH terms:
Chronic Disease
Heart Failure
Inflammation
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Cardiovascular Diseases
Disease Attributes
Heart Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 23, 2014